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Pre~ently, the list of advantages of oncology PET/eT is growing longer as more studies are being 
p'ublls~ed .. Although p.ET/eT seems r~lativ~ly expensive, it should now be considered a first choice 
.lllve~tlgatlOnfor stagmg. and ~e-stagmg of most cancer pathologies, together with complementary 
lm~gmg and laboratory mvestlgations. The advantages outweigh the apparent 'expense drawback' 
smce the increased se~sibility, . .}pecificity and accuracy of this methodology over stand-alone eT 
allows better therapeutic planmng and follow-up, and this could substantially reduce overall costs, 
where and when availablel.2. 
Further advantages of current 
PET/eT Technology 
1. Economical aspects: For example 
Zubeldia et al l (University at Buffalo, 
New York) analysed in detail the costs 
of adding '8FDG-PET to CT 
preoperatively in colorectal cancer 
patients with resectable hepatic 
metastases l . CT with and without ISFDG_ 
PET was compared among patients with 
colorectal cancer in staging for surgical 
resection of hepatic metastases. 
Complication rates and costs for CT, 
'SFDG PET/CT, and surgical procedures 
were also obtained. The average expected 
surgical cost per patient when ISFDG-
PET was used to determine the presence 
of extrahepatic disease was US$16,278 
compared to $21,547 for conventionll] 
management: a net savings of $5,269 
which results from the unique ability of 
'SFDG-PET in excluding patients with 
extrahepatic disease, and avoiding 
unnecessary surgical expenses. Another 
group of researchers supported by the 
Ontario Ministry of Health and Long 
Term Care have recently published a 
similar study for non-small cell lung 
carcinoma (NSCLC)2. In NSCLC, 
staging with PET/CT better identifies 
those patients with mediastinal and 
extrathoracic disease, sparing some from 
stage-inappropriate surgery. Once again, 
this strategy has an economic impact by 
avoiding costs related to unnecessary 
surgery, besides the costs related to 
staging abdominal cr and bone scan 
(an average total of $900 per patient for 
the latter two investigations), and also 
impacts on patient safety by avoiding 
CT-associated radiation exposure and 
risk of nephrotoxicity (due to contrast 
medium). PET/CT lmaging for the 
preoperative assessment of potentially 
resectable NSCLC is now being used 
widely in Ontario. One must also keep 
F!gure 1. A singl~ whol~-body sc~n allows comprehensive TNM staging of 
dlseas~ both a~ dzagnosls and dunng follow-up. In the first image on the left, 
~he pnmr:ry T .IS marke~ by the arrow. Mediastinal Lymph Nodes are marked 
zn the m~ddle Image. LIver and lung metastases are shown in the third image 
on t~e nght. ImClges courtesy of San Raffaele Hospital, Milan . 
in mind that with one dose and one 
examination a whole-body scan is 
acquired, therefore all organs are 
examined for metastases. 
2. Earlier diagnosis and assessment of 
response to treatment: Another practical 
example is the early diagnosis of 
peritoneal carcinomatosis with 'SFDG 
PET/CT which shows superior 
sensitivities and positive predictive values 
over stand-alone cr.3 Already discussed 
in the previous article is the usefulness 
of PET/CT in the earlier identification of 
the cause of rising tumour markers. 
Assessment of response to therapy has 
also been extensively discussed 
previously. Of particular interest is the 
essential role ofPET/CT in lymphomas. 
3. Clear characterisation of findings: 
Other studies demonstrate how high 
resolution conventional radiological 
techniques manage to identify 
unsuspected, clinically silent adrenal 
lesions (incidentalomas) 
morphologically, but fail to distinguish 
benign from malignant. A 
distinguishing methodology is essential 
in such cases considering that most 
incidentalomas are benign adenomas 
(70-94%) and that adenomas are 
common in the general population (2-
9%). '8FDG PET/CT reaches a 
specificity and sensitivity close to 
100%.4.5 As already explained in the 
previous article, PET /CT is very useful 
in the characterisation of most 
pulmonary nodules, especially those 
which are difficult to reach with a 
biopsy needle. The same concept 
applies for indeterminate pancreatic, 
liver or spleen lesions , and residual 
masses after therapy. 
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4. Better staging and/or restaging: One example is yet 
another study in which the efficacy of 18FDG-PET was 
evaluated and its impact in staging of patients with newly 
diagnosed breast cancer was assessed.6 271 patients with 
biopsy-proven primary breast cancer were examined. PET 
results were compared with the histopathology results. In 
this particular study the sensitivity of 18FDG-PET for 
detecting axillary lymph node metastasis was 100% in pN3, 
and the specificity was 89% for pNO stage. Detection of 
extra-axillary regional node or distant metastatic lesions 
revealed by PET scan in 22 of 24 patients resulted in a 
significant change in the TNM stage. Distant metastasis 
without axillary lymph node metastasis was noted in 21 % 
(5/24) of patients. The results revealed that 18FDG-PET 
upgraded TNM stage in 9.2% (22/240) of patients and 7.5% 
(18/240) of patients were diagnosed as having one or more 
distant metastases. 18FDG-PET was able to identify extra-
axillary regional nodal and distant lesions in newly diagnosed 
patients with breast cancer and altered the staging and 
management of therapy in patients with newly diagnosed 
breast cancer. There are numerous other examples in 
scientific literature which one may read abouC-IO. 
5. Use in patients allergic to contrast medium or in whom 
CT is contraindicated: Adverse reactions from contrast medium 
administration can occur and symptoms can range from mild 
to life-threatening. Serious side-effects include an anaphylaxis-
like reaction and kidney damage which may occur because 
the contrast media are eliminated renally. There is no such risk 
in carrying out PET/CT since contrast media are not involved. 
Thus PET/CT can be carried out by patients who are allergic 
to contrast medium and by patients who cannot carry out a 
CT scan ·with contrast medium due to deranged creatinine 
levels or history of kidney problems. 8J 
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